PROJECT 1- AMYLOID AND TAU PET Trajectories of a? and tau deposition can now be related to each other and to other biomarkers of preclinical AD as well as to clinical endpoints. Recent therapeutic trial failures highlight the critical need for a better understanding of how changing levels of pathology relate to each other and to clinical outcomes. Unfortunately, these relationships are complex, and optimized measures permitting robust tracking of dynamics remain underdeveloped, posing a barrier to efficient, rapid progress toward successful therapeutics. Initial study of these trajectories in HABS indicated that earlier a? increase was detectable but was not associated with cognitive decline until a later observation period, during which time the decline was mediated by concurrent measures of tau accumulation. In the proposed HABS Cycle 3, Project 1 will focus on the progression and interrelated dynamics of a? and tau pathologies assessed with PET acquired in the Imaging Core to identify stages of pathologic progression. We will leverage the HABS sample, with 9 years of amyloid and 4 years of tau PET follow up along with longitudinal neuropsychological data to characterize stages of progression in terms of time (Aim 1) and space (Aim 2), as well as explore novel plasma measures for manifestations of these stages (exploratory Aim 3). Specifically, HABS participants will undergo serial imaging with 11C Pittsburgh Compound B and 18F Flortaucipir PET with Aim 1, to characterize the temporal trajectory of each pathology, relate these trajectories to each other, identify dynamic connections between each that progress in successive intervals, and relate these findings to age, sex, and APOE genotype;
Aim 2, to identify the specific anatomy of a? and tau progression based on serial measures;
and Aim 3 (Exploratory), investigate the associations of a? and tau level and change measured with PET to measures obtained with blood biomarkers, and to correlate findings with autopsy brains as they become available. Project 1 will contribute to the overall Program goals: together we will assess the impact of modulating factors (Project 2) as well as the functional links (Project 3) that relate pathologic change to clinical phenotype (Project 4). Together, this research will ultimately improve sampling for clinical trials and therapeutic targeting strategies.
| Properzi, Michael J; Buckley, Rachel F; Chhatwal, Jasmeer P et al. (2018) Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. Neuroimage 186:446-454 |
| Hanseeuw, Bernard J; Jonas, Victoria; Jackson, Jonathan et al. (2018) Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Mol Psychiatry : |
| Lee, Catherine; Betensky, Rebecca A; Alzheimer's Disease Neuroimaging Initiative (2018) Time-to-event data with time-varying biomarkers measured only at study entry, with applications to Alzheimer's disease. Stat Med 37:914-932 |
| Jacobs, Heidi I L; Hedden, Trey; Schultz, Aaron P et al. (2018) Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci 21:424-431 |
| Chiou, Sy Han; Austin, Matthew D; Qian, Jing et al. (2018) Transformation model estimation of survival under dependent truncation and independent censoring. Stat Methods Med Res :962280218817573 |
| Qian, Jing; Chiou, Sy Han; Maye, Jacqueline E et al. (2018) Threshold regression to accommodate a censored covariate. Biometrics : |
| Orlovsky, Irina; Huijbers, Willem; Hanseeuw, Bernard J et al. (2018) The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults. Alzheimers Dement (Amst) 10:121-129 |
| Quiroz, Yakeel T; Sperling, Reisa A; Norton, Daniel J et al. (2018) Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurol 75:548-556 |
| Chhatwal, Jasmeer P; Schultz, Aaron P; Johnson, Keith A et al. (2018) Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. Brain 141:1486-1500 |
| Hanseeuw, Bernard J; Betensky, Rebecca A; Mormino, Elizabeth C et al. (2018) PET staging of amyloidosis using striatum. Alzheimers Dement 14:1281-1292 |
Showing the most recent 10 out of 170 publications
